Chiesi hopes to lower Scope 3 emissions by changing the propellant used in its inhalers, said Harriet Lewis, director of market access and public affairs at Chiesi. Image Credit: 3rdtimeluckystudio / Shutterstock.

UK-based Chiesi has invested in reducing its carbon footprint, with the development of a new inhaler propellant and the purchase of carbon credits to offset its carbon emissions.

The majority of Chiesi’s portfolio consists of inhalers that have a propellant gas with a high potential to have an impact on global warming. The company hopes to lower that potential and its Scope 3 emissions by changing the propellant, said Harriet Lewis, public affairs and communications director at Chiesi UK & Ireland, in an interview with Pharmaceutical Technology.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The new carbon minimal inhaler will replace the current hydrofluorocarbon propellant (HFC 134a) with the low global warming potential propellant (HFC 152a). Chiesi will also seek regulatory approval for the product with the new propellant, said Lewis.

Chiesi has invested €350m ($372.8m) for the development of the new propellant, as per Lewis. The use of new propellant is expected to reduce the company’s Scope 3 emissions by 90%, compared to those in 2019.

Earlier this month, Chiesi started the Phase III TRECOS clinical study (NCT06264674) for the new carbon-minimal inhaler. The development of the new propellant is part of the company’s plan to achieve net zero greenhouse gas (GHG) emissions by 2035.

See Also:

In recent years, with multiple pharma companies have made net zero commitments. In November 2023, GSK announced plans to start Phase III trials of a low-carbon version of its metered dose inhaler (MDI), Ventolin (salbutamol), using a next-generation propellant. The current propellant accounts for 49% of the company’s carbon footprint, with the new variation expected to reduce the greenhouse gas emissions from the use of the inhaler by approximately 90%.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Chiesi has also purchased and retired carbon removal credits to offset the carbon emissions of the company’s entire UK portfolio of respiratory medicines. The company also plans to reduce its Scope 3 emissions through the reevaluation of its supply chain.

“Chiesi has high standards and expects its suppliers to be verified through the EcoVardis verification platform,” said Lewis. She added, “The platform is evolving and the company plans to introduce new standards and competencies for for its suppliers over the next 12-18 months. So, it is not just about us being a responsible manufacturer, we also expect the responsibility to translate and be passed down the value chain.”